← Back to patent-cliff list
TQB-3201
Tier C — Watch / tradeTQB-3201
-
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：AR
Indications (approved)：Castration-resistant prostate cancer, Prostate cancer
Regional status
US
-
EU
-
China
Phase II
2025-09-01
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of TQB-3201?
Approved indications include: Castration-resistant prostate cancer, Prostate cancer.
When does the TQB-3201 patent expire?
No public expiry year is available for TQB-3201 yet; this page updates once verified.
How do I get a quote for TQB-3201 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-30